Absci
ABSIAbsci is a clinical-stage drug developer that uses artificial intelligence to design its own antibody medicines, led by a candidate for hair loss and endometriosis. We follow it because it may gain indirectly as artificial intelligence spreads through the businesses it serves.
- Ticker
- ABSI
- Exchange
- —
- Price
- —
- Change
- —
- As of
- —
- Market cap
- —
- EV/EBIT
- —
- P/E NTM
- —
- FCF yield
- —
- Net debt/EBITDA
- —
- Next earnings
- —
The living report
Bears on our standing view that AI's economy-wide productivity lift does not arrive before 2028. It is proved wrong if productivity jumps much sooner than we expect, or adoption stops spreading.
Members: queues this company for a report on a coming night.
The market record
Free during the preview. Each figure shows only where two independent data providers, Massive and Yahoo, agree on it to the cent; a figure they do not agree on is left out. Dated, not live. It describes; it does not recommend.
close of 6 Nov 2026 · Massive and Yahoo agree
6 Nov 2026 · both providers agree
the 6 Nov 2026 close × 171,614,010 shares outstanding on the 10-Q cover, as of 31 Jul 2026
Filings
Newest first, from EDGAR. Where a piece read a filing, one line of what it said.
Where it sits in the frame
Reports next
Latest disclosed
What it has disclosed
Newest first. Every figure traces to a filing; "Show sources" shows which.
Mentioned in
Every piece that names this company, newest first: what it said, and the standing view it bore on. Written when the piece is committed; never edited, never removed.
Same question
Other companies under Who may gain as AI spreads through other businesses?
This entry
Prices on this page are dated market records, shown free during the preview, each confirmed by two independent data providers. None is a recommendation.
Record
Written according to the Grant Bishop standard — machine-researched, machine-checked, human-judged; then read and committed by the publisher. Every number traces to a filing or a dated market record; every claim carries a date and what would prove it wrong.
- Verification
- multi-source verified, machine-drafted, human-gated
- As of
- 2026-08-11
- Position disclosure
- The publisher holds index-level U.S. equity exposure and no direct position in any single name discussed.
- Not advice
- General commentary for a general audience. Not advice for your situation.